DK2256106T3 - 3,4-disubstituterede 1 H-pyrazolforbindelser og anvendelse heraf som cyclin-afhængige kinaser (CDK) og glycogensyntase kinase-3- (GSK-3) modulatorer - Google Patents

3,4-disubstituterede 1 H-pyrazolforbindelser og anvendelse heraf som cyclin-afhængige kinaser (CDK) og glycogensyntase kinase-3- (GSK-3) modulatorer Download PDF

Info

Publication number
DK2256106T3
DK2256106T3 DK10175329.1T DK10175329T DK2256106T3 DK 2256106 T3 DK2256106 T3 DK 2256106T3 DK 10175329 T DK10175329 T DK 10175329T DK 2256106 T3 DK2256106 T3 DK 2256106T3
Authority
DK
Denmark
Prior art keywords
groups
group
carbocyclic
formula
mmol
Prior art date
Application number
DK10175329.1T
Other languages
English (en)
Inventor
Valerio Berdini
Maria Grazia Carr
Alison Jo-Ann Woolford
Andrew James Woodhead
Paul Graham Wyatt
Michael Alistair O'brien
Theresa Rachel Early
Adrian Liam Gill
Gary Trewartha
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Priority claimed from EP04743512A external-priority patent/EP1651612B9/en
Application granted granted Critical
Publication of DK2256106T3 publication Critical patent/DK2256106T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (14)

  1. - 1 - PATENKRAV
    1. Kombination omfattende: (i) en forbindelse med formlen (II):
    v-I) eller salte eller tautomere eller N-oxider eller solvater deraf; hvor Y er en binding eller en alkylenkæde af 1,2 eller 3 carbonatomer i længden; R1 er en carbocyklisk eller heterocyklisk gruppe med fra 3 til 12 ringelementer, hvor de carbocykliske eller heterocykliske grupper er ikke-substituerede eller substitueret med én eller flere substituentgrupper R10; R2 er hydrogen eller methyl; R3 er udvalgt fra ikke-aromatiske carbocykliske eller heterocykliske grupper med fra 3 til 12 ringelementer, hvor de carbocykliske eller heterocykliske grupper er ikke-substituerel eller substitueret med én eller flere substituentgrupper R10; og R10 er udvalgt fra halogen, hydroxy, trifluormethyl, cyano, nitro, carboxy, amino, monoeller di-C14 hydrocarbylamino, carbocycliske og heterocykliske grupper med fra 3 til 12 ringelementer; en gruppe Ra-Rb, hvor Ra er en binding, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, S02, NRC, S02NR° eller NRcS02; og Rb er udvalgt fra hydrogen, carbocycliske og heterocykliske grupper med fra 3 til 12 ringelementer, og en Ci.8-alkylgruppe eventuelt substitueret med én eller flere substituenter udvalgt fra hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- eller di-C1.4-hydrocarbylamino, carbocycliske og heterocykliske grupper med fra 3 til 12 ringelementer; R° er udvalgt fra hydrogen og C14-hydrocarbyl; og X1 er O, S eller NR° og X2 er =0, =S eller =NR°; og forudsat at, hvor substituentgruppen R10 omfatter eller indbefatter en carbocyklisk eller heterocyklisk gruppe, kan den carbocykliske eller heterocykliske gruppe være ikke-si ihstiti leret filler kan selv være snhstitueret med én eller flere vderliaere -2- substituentgrupper R10 og, hvor (a) sådanne yderligere substituentgrupper R10 indbefatter carbocykliske eller heterocykliske grupper, der ikke selv er yderligere substitueret; eller (b) de yderligere substituenter ikke indbefatter carbocykliske eller heterocykliske grupper, men ellers er udvalgt fra grupperne anført ovenfor i definitionen af R10; og (ii) ét eller flere andre terapeutiske midler.
  2. 2. Kombination ifølge krav 1, hvor R2 er hydrogen.
  3. 3. Kombination ifølge et hvilket som helst af de foregående krav, hvor R1 er en ikke-substitueret eller substitueret monocyklisk carbocyklisk eller heterocyklisk gruppe, hvor de carbocycliske og heterocykliske grupper er substitueret med én eller flere substituentgrupper R10 eller R10a; hvor R10 er som defineret i krav 1 og R10a er udvalgt fra halogen, hydroxy, trifluormethyl, cyano, nitro, carboxy, en gruppe Ra-Rb, hvor Ra er en binding, O, CO, X3C(X4), C(X4)X3, X3C(X4)X3, S, SO, eller S02, og Rb er udvalgt fra hydrogen og en C^-alkylgruppe eventuelt substitueret med én eller flere substituenter udvalgt fra hydroxy, oxo, halogen, cyano, nitro, carboxy og monocyklisk ikke-aromatiske carbocykliske eller heterocykliske grupper med fra 3 til 6 ringelementer.
  4. 4. Kombination ifølge krav 1, hvor forbindelsen med formlen (II) har formlen (IV):
    vJV) eller salte eller tautomere eller N-oxider eller solvater deraf; hvor R1 og R2 er som defineret i et hvilket som helst af de foregående krav; en eventuel anden binding kan være til stede mellem carbonatomer nummereret 1 og 2; én af U og T er udvalgt fra CH2, CHR13, CR11R13, NR14, N(0)R15, O og S(0)t; og den anden af U og T er udvalgt fra NR14, O, CH2, CHR11, C(R11)2, og C=0; r er 0, 1, 2, 3 eller 4; t er 0,1 eller 2; -3 - R11 er udvalgt fra hydrogen, halogen, C^-alkyl og C^-alkoxy; R13 er udvalgt fra hydrogen, NHR14, NOH, NOR14 og Ra-Rb; R14 er udvalgt fra hydrogen og Rd-Rb; Rd er udvalgt fra en binding, CO, C(X2)X1, S02 og S02NRc; Ra, Rb og R° er som defineret i et hvilket som helst af de foregående krav; og R15 er udvalgt fra mættet C14-hydrocarbyl eventuelt substitueret med hydroxy, C^-alkoxy, halogen eller en monocyklisk 5- eller 6-leddet carbocyklisk eller heterocyklisk gruppe, forudsat at U og T ikke samtidigt kan være O.
  5. 5. Kombination ifølge krav 4, hvor forbindelsen med formlen (II) har formlen (Va):
    eller salte eller tautomere eller N-oxider eller solvater deraf; hvor R14a er udvalgt fra hydrogen, C^-alkyl eventuelt substitueret med fluor, cyclopropylmethyl, phenyl-C^-alkyl, C^-alkoxycarbonyl, phenyl-C^-alkoxycarbonyl, Ci. ^alkoxy-C^-alkyl og C^-alkylsulphonyl, hvor phenyldelene, når de er til stede, eventuelt er substitueret med én til tre substituenter udvalgt fra fluor, chlor, C^-alkoxy eventuelt substitueret med fluor eller C^-alkoxy, og 4-alkyl eventuelt substitueret med fluor eller C^-alkoxy; w er 0,1,2 eller 3; R2 er hydrogen eller methyl; R11 og r er som defineret i et hvilket som helst af kravene 17 til 19; og R19 er udvalgt fra fluor; chlor; C^-alkoxy eventuelt substitueret med fluor eller C^-alkoxy; og Ci-4-alkyl eventuelt substitueret med fluor eller Ci.2-alkoxy.
  6. 6. Kombination ifølge krav 1, hvor forbindelsen med formlen (II) —.21a
    \ v ιυ; eller salte eller tautomere eller N-oxider eller solvater deraf; hvor R20 er udvalgt fra hydrogen og methyl; R21a er udvalgt fra fluor og chlor; og R22a er udvalgt fra fluor, chlor og methoxy.
  7. 7. Kombination ifølge krav 6, hvor forbindelsen med formlen (II) er 4-(2,6-dichlor-benzoylamino)-1 H-pyrazol-3-carboxylsyre piperidin4-yl-amid eller et salt deraf.
  8. 8. Kombination ifølge et hvilket som helst af de foregående krav, hvor det ene eller flere andre terapeutiske midler er udvalgt fra anticancermidler indbefattende: - topoisomeraseinhibitorer - alkylerende midler - antimetabolitter - DNA-bindere - mikrotubulusinhibitorer (tubulin-targetternede midler) - monoklonale antistoffer - signaltransduktioninhibitorer - radioterapi.
  9. 9. Kombination ifølge et hvilket som helst af de foregående krav, hvor det ene eller flere andre terapeutiske midler er udvalgt fra anticancermidler indbefattende cisplatin, cyclophosphamid, doxorubicin, irinotecan, fludarabin, 5FU, taxaner og mitomycin C.
  10. 10. Kombination ifølge et hvilket som helst af de foregående krav, hvor forbindelsen med formlen (II) og det ene eller flere andre terapeutiske midler administreres enten samtidigt -5 -
  11. 11. Kombination ifølge et hvilket som helst af de foregående krav, hvor forbindelsen med formlen (II) og ét, to, tre, fire eller flere andre terapeutiske midler er formuleret sammen i den doseringsform indeholdende to, tre, fire eller flere terapeutiske midler.
  12. 12. Kombination ifølge et hvilket som helst af de foregående krav til anvendelse i medicin, for eksempel til behandling af en cancer.
  13. 13. Farmaceutisk sammensætning (f.eks. formulering) omfattende mindst én forbindelse med formlen (II) som defineret i et hvilket som helst af kravene 1 til 7 sammen med ét eller flere farmaceutisk acceptable bærestoffer, hjælpemidler, excipienser, fortyndingsmidler, fyldstoffer, buffere, stabiliseringsmidler, konserveringsmidler, smøremidler og andre terapeutiske eller profylaktiske midler.
  14. 14. Forbindelse med formlen (II) som defineret i et hvilket som helst af kravene 1 til 7 til anvendelse i behandlingen af en sygdom, der er: - virusinfektioner, for eksempel herpes virus, pox virus, Epstein-Barr virus, Sindbis virus, adenovirus, HIV, HPV, HCV og HCMV; forebyggelse af udvikling af AIDS hos HIV-smittede individer; eller - type II eller ikke-insulinafhængig diabetes mellitus; eller - autoimmune sygdomme; eller - hovedtraume; eller - apopleksi; eller - epilepsi; eller - neurodegenerative forstyrrelser, for eksempel Alzheimers sygdom, AlDS-relateret demens, Parkinsons sygdom, amyotropisk lateral sklerose, retinitis pigmentosa, spinalmuskulær atropi og cerebellar degeneration, eller såsom Alzheimers, motorneuronsygdom, progressiv supranuklear parese, kortikobasal degeneration og Picks sygdom; eller - kroniske inflammatoriske sygdomme, for eksempel systemisk lupus erythematosus, autoimmunmedieret glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatorisk tarmsygdom, og autoimmun diabetes mellitus; eller - cardiovaskulære sygdomme for eksempel hjertehypertrofi, restenose og atherosklerose, eller såsom arrhythmia; eller - glomerulonephritis; eller - myelodysplastisk syndrom; eller -6- - iskæmisk skadeassocieret myokardieinfarkt, apopleksi og reperfusionsskade; eller - toxin-inducerede eller alkoholrelaterede leversygdomme; eller - hæmatologiske sygdomme, for eksempel, kronisk anæmi og aplastisk anæmi; eller - degenerative sygdomme i bevægeapparatet, for eksempel, osteoporose og arthritis, eller - aspirin-senstiv rhinosinusitis; eller - cystisk fibrose; eller - multipel sklerose, eller - nyre sygdomme; eller - cancersmerte; eller - cancer, navnlig RB+ve tumorer.
DK10175329.1T 2003-07-22 2004-07-22 3,4-disubstituterede 1 H-pyrazolforbindelser og anvendelse heraf som cyclin-afhængige kinaser (CDK) og glycogensyntase kinase-3- (GSK-3) modulatorer DK2256106T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48904603P 2003-07-22 2003-07-22
GBGB0317127.9A GB0317127D0 (en) 2003-07-22 2003-07-22 Pharmaceutical compounds
US56976304P 2004-05-10 2004-05-10
EP04743512A EP1651612B9 (en) 2003-07-22 2004-07-22 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators

Publications (1)

Publication Number Publication Date
DK2256106T3 true DK2256106T3 (da) 2015-06-01

Family

ID=27772442

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10175329.1T DK2256106T3 (da) 2003-07-22 2004-07-22 3,4-disubstituterede 1 H-pyrazolforbindelser og anvendelse heraf som cyclin-afhængige kinaser (CDK) og glycogensyntase kinase-3- (GSK-3) modulatorer
DK04743512.8T DK1651612T5 (da) 2003-07-22 2004-07-22 3,4-Disubstituerede 1H-pyrazolforbindelser og deres anvendelse som cyclinafhængige kinaser (CDK) og glykogensynthasekinase-3-(GSK)-modulatorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04743512.8T DK1651612T5 (da) 2003-07-22 2004-07-22 3,4-Disubstituerede 1H-pyrazolforbindelser og deres anvendelse som cyclinafhængige kinaser (CDK) og glykogensynthasekinase-3-(GSK)-modulatorer

Country Status (11)

Country Link
CN (1) CN1826323B (da)
AT (1) ATE553091T1 (da)
DK (2) DK2256106T3 (da)
ES (2) ES2539480T3 (da)
GB (1) GB0317127D0 (da)
HU (1) HUE025425T2 (da)
PT (2) PT1651612E (da)
RU (1) RU2408585C2 (da)
SI (2) SI1651612T1 (da)
TW (1) TWI356823B (da)
ZA (1) ZA200600313B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
US9200008B2 (en) * 2010-07-02 2015-12-01 Aska Pharmaceutical Co., Ltd. Heterocyclic compound and p27Kip1 degradation inhibitor
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN104592251B (zh) * 2015-01-23 2019-10-01 上海复星医药产业发展有限公司 4-(稠杂环取代氨基)-1h-吡唑-3-甲酰胺类化合物及其用途
EP3310783B1 (en) * 2015-06-18 2020-11-04 Ting Therapeutics LLC Compositions for the prevention of hearing loss
CN107245073B (zh) * 2017-07-11 2020-04-17 中国药科大学 4-(芳杂环取代)氨基-1h-3-吡唑甲酰胺类flt3抑制剂及其用途
KR102661053B1 (ko) * 2018-04-26 2024-04-26 화이자 인코포레이티드 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체
CN111848579B (zh) * 2019-04-26 2023-11-14 君实润佳(上海)医药科技有限公司 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药

Also Published As

Publication number Publication date
DK1651612T3 (da) 2012-07-23
ES2539480T3 (es) 2015-07-01
SI1651612T1 (sl) 2012-09-28
DK1651612T5 (da) 2012-10-22
PT1651612E (pt) 2012-07-06
ATE553091T1 (de) 2012-04-15
GB0317127D0 (en) 2003-08-27
SI2256106T1 (sl) 2015-10-30
RU2006105338A (ru) 2007-09-20
HUE025425T2 (en) 2016-02-29
PT2256106E (pt) 2015-07-22
CN1826323A (zh) 2006-08-30
CN1826323B (zh) 2012-06-27
ZA200600313B (en) 2007-02-28
TW200524877A (en) 2005-08-01
ES2385328T3 (es) 2012-07-23
RU2408585C2 (ru) 2011-01-10
TWI356823B (en) 2012-01-21

Similar Documents

Publication Publication Date Title
EP1651612B9 (en) 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
US20100160324A1 (en) Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2006077414A1 (en) Pyrazole derivatives for the inhibition of cdk' s and gsk' s
US20080167309A1 (en) Pharmaceutical Compounds
WO2005002552A2 (en) Benzimidazole derivatives and their use as protein kinases inhibitors
DK2256106T3 (da) 3,4-disubstituterede 1 H-pyrazolforbindelser og anvendelse heraf som cyclin-afhængige kinaser (CDK) og glycogensyntase kinase-3- (GSK-3) modulatorer
KR101190964B1 (ko) 벤즈이미다졸 유도체 및 단백질 키나제로서의 그의 용도